Ghent-based healthtech startup Nuclivision has raised €5 million in a seed funding round to enhance its PET image enhancement software across the US and Europe. The round was co-led by LUMO Labs and Heran Partners.
- Founded in 2022 by Tomas Brants, Maarten Larmuseau, and Simon DeKeyser, Nuclivision develops software to improve PET (positron emission tomography) imaging, aiding in the early detection and diagnosis of diseases like cancer and Alzheimer’s.
- The company's main product, Nuclarity, uses image enhancement algorithms that enable lower-dose PET scans while maintaining image quality and diagnostic accuracy.
- Nuclarity is designed to integrate seamlessly into existing clinical workflows, supporting the entire process from image acquisition to interpretation and follow-up.
"Medical imaging is at an inflection point. With the rapid growth within radiopharma and theranostics, the use of AI and smart software is becoming necessary to handle the increased demand for PET and SPECT scans for conditions such as cancer and Alzheimer's," CEO of Nuclivision, Maarten Larmuseau, stated.
Details of the deal
- The seed round was co-led by LUMO Labs, a Dutch venture capital firm that launched the €100 million LUMO Rise Fund to support impact-driven startups. Heran Partners, with support from Ghent's imec.istart future fund.
"Nuclivision is uniquely positioned in the field of AI-driven image enhancement for PET scans with the Nuclarity platform. Nuclarity not only reduces the time pressure on nuclear medicine departments but also the cost and harmful environmental and health impact of PET scans," Geoffrey D’hondt from Heran Partners, commented.
- The fresh capital will enable Nuclivision to finish regulatory approval, launch Nuclarity in Europe and the US, grow its team, and improve its software for wider hospital use.
